Início › Linfoma de Burkitt › Pensilvânia
Ensaios clínicos de Linfoma de Burkitt em Pensilvânia
18 estudos para Linfoma de Burkitt estão buscando participantes em locais em Pensilvânia.
Cidades em Pensilvânia
Texto oficial do estudo (Inglês)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Penn State Children's Hospital, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- e mais 2
RecrutandoFase 2
366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- e mais 1
RecrutandoFase 3
Idades de 18 a 39 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT03150693Blinatumomab Consolidation in Real World
- University of Pennsylvania, Philadelphia
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoEstudo observacional
Idades de 0 a 38 · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e mais 2
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Children's Hospital of Philadelphia (Data Collection Only), Philadelphia
RecrutandoFase 3
Idades 1 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
RecrutandoFase 1/2
6 Months – 25 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoFase 1
Idades de 0 a 18 · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e mais 3
RecrutandoFase 2
Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e mais 3
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoFase 2
Idades de 7 a 25 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05082519Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- UPMC Hillman Cancer Center, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 31 de jul. de 2026 · NCT07069699CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
Recrutando
Até 25 anos · Todos os sexos · Atualizado em 8 de jul. de 2026 · NCT03810196Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoFase 1/2
Idades de 0 a 29 · Todos os sexos · Atualizado em 26 de mai. de 2026 · NCT05480449Co-administration of CART22-65s and huCART19 for B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoFase 1/2
Até 29 anos · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT05674175Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Children's Hospital of Philadelphia, Philadelphia
RecrutandoFase 1/2
Idades de 15 a 50 · Todos os sexos · Atualizado em 9 de set. de 2025 · NCT04150497Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
RecrutandoFase 2
Idades de 18 a 79 · Todos os sexos · Atualizado em 13 de jan. de 2025 · NCT05281809Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.